Terns Prescribed drugs (NASDAQ:TERN) stated late Thursday that it expects to report topline information from a Part 1 examine for its oral GLP-1 drug TERN-601 within the remedy of weight problems within the second half of 2024.
The biotech firm additionally expects to launch interim information within the second half of 2024 from a Part 1 trial of its drug TERN-701 within the remedy of persistent myelogenous leukemia, or CML.
Terns issued the updates along with the release of its Q4 earnings report, which met Avenue expectations. The corporate added that it had money and equivalents of $263M on the finish of 2023, which must be adequate to fund operations into 2026.
Terns is considered one of a number of biopharma firms engaged on GLP-1 medicine for weight reduction. Different firms embrace AstraZeneca (AZN), Amgen (AMGN), Pfizer (PFE), Altimmune (ALT), Viking Therapeutics (VKTX) and Construction Therapeutics (GPCR).
The GLP-1 market is at present dominated by Eli Lilly (LLY) and Novo Nordisk (NVO).
Extra on Terns Prescribed drugs
Terns Prescribed drugs (NASDAQ:TERN) stated late Thursday that it expects to report topline information from a Part 1 examine for its oral GLP-1 drug TERN-601 within the remedy of weight problems within the second half of 2024.
The biotech firm additionally expects to launch interim information within the second half of 2024 from a Part 1 trial of its drug TERN-701 within the remedy of persistent myelogenous leukemia, or CML.
Terns issued the updates along with the release of its Q4 earnings report, which met Avenue expectations. The corporate added that it had money and equivalents of $263M on the finish of 2023, which must be adequate to fund operations into 2026.
Terns is considered one of a number of biopharma firms engaged on GLP-1 medicine for weight reduction. Different firms embrace AstraZeneca (AZN), Amgen (AMGN), Pfizer (PFE), Altimmune (ALT), Viking Therapeutics (VKTX) and Construction Therapeutics (GPCR).
The GLP-1 market is at present dominated by Eli Lilly (LLY) and Novo Nordisk (NVO).